DIVI'S LABORATORIES LTD. - 532488 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of schedule of investors meeting to be held on 13.03.2023.11-03-2023
11-03-2023
Here's What ChatGPT Chose Between Laurus And Divis Labs
How ChatGPT refused to compare two pharma stocks and left the decision to us.03-03-2023
DIVI'S LABORATORIES LTD. - 532488 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Q3FY23 earnings conference call held on February 03, 202308-02-2023
DIVI'S LABORATORIES LTD. - 532488 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for SBI Funds Management Ltd08-02-2023
DIVI'S LABORATORIES LTD. - 532488 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper clippings - Extracts of unaudited financial results for the quarter and nine months ended December 31, 202204-02-2023
Divi's Laboratories Results Earnings Call for Q3FY23
Conference Call with Divi's Laboratories Management and Analysts on Q3FY23 Performance and Outlook. Listen to the full earnings transcript.03-02-2023
DIVI'S LABORATORIES LTD. - 532488 - Audio Recording Of Earnings Conference Call Q3FY23 Held On February 03, 2023
Further to our intimation letter dated January 25, 2023, we hereby inform that the audio recording of the earnings conference call for the quarter and nine ended December 31, 2022, held on February 03, 2023 at 14.00 Hrs IST has been uploaded on the Company's website at the following weblink: https://www.divislabs.com/wp-content/uploads/2023/02/Earnings-Call-Audio-Q3FY23.mp303-02-2023
Q3FY23 Quarterly Result Announced for Divi's Laboratories Ltd.
Pharmaceuticals firm Divi's Laboratories announced Q3FY23 results: Consolidated Q3FY23 & 9MFY23: Divi’s Laboratories has earned a consolidated total income of Rs 1,822 crores for Q3FY23 as against a total income of Rs 2,510 crores during the corresponding quarter of last year. Profit before Tax (PBT) for Q3FY23 accounted to Rs 436 crores, as against a PBT of Rs 1,034 crores during the corresponding quarter of last year. Profit after Tax (PAT) for the current is Rs 307 crores as against a PAT of Rs 902 crores for the corresponding quarter of last year. For the 9MFY23, the company earned a PAT of Rs 1,502 crores on a total income of Rs 6,099 crores, as against a PAT of Rs 2,066 crores on a total income of Rs 6,503 crores during the corresponding previous period. Result PDF03-02-2023
DIVI'S LABORATORIES LTD. - 532488 - Outcome Of Board Meeting - Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Nine Months Ended December 31, 2022
Further to our intimation dated January 23, 2023, we would like to inform that the Board of Directors of the Company at its meeting held on February 03, 2023 has, inter alia approved the unaudited financial results for the quarter and nine months ended December 31, 2022. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we enclose herewith the following: 1. Unaudited standalone financial results for the quarter and nine months ended December 31, 2022 along with Limited Review Report of the Statutory Auditors thereon. 2. Unaudited consolidated financial results for quarter and nine months ended December 31, 2022 along with Limited Review Report of the Statutory Auditors thereon. 3. Press Release on the said financial results of the Company.03-02-2023